4-chloro-1H-pyrrolo[2,3-b]pyridine-N-oxide meta-chlorobenzoic acid | 935466-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 4-chloro-1H-pyrrolo[2,3-b]pyridine-N-oxide meta-chlorobenzoic acid
• 英文别名: 4-chloro-1H-pyrrolo[2,3-b]pyridine-7-oxide 3-chlorobenzoic acid salt；4-chloro-1H-pyrrolo [2,3-b]pyridine 7-oxide 3-chlorobenzoate；4-chloro-1H-pyrrolo[2,3-b]pyridine 7-oxide 3-chlorobenzoate；4-chloro-7-azaindole-N-oxide m-chlorobenzoic acid
• CAS: 935466-76-5
• 化学式: C₇H₅ClN₂O*C₇H₅ClO₂
• 分子量: 325.151
• InChiKey: BLISJRJHMFMRJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.49
• 重原子数：
  21.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.03
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  4-chloro-1H-pyrrolo[2,3-b]pyridine-N-oxide meta-chlorobenzoic acid 在 吡啶 、 硫酸二甲酯 作用下， 以 乙腈 为溶剂， 反应 85.0h， 生成 N-(4-chloro-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclopropanecarboxamide
  参考文献：
  名称：

  단백질 키나제 억제제로서의 헤테로고리 화합물

  摘要：

  本发明提供了具有蛋白激酶抑制活性的新化合物，其立体异构体或药学上可接受的盐。根据本发明的化合物，其立体异构体或药学上可接受的盐通过表现出蛋白激酶抑制活性，在预防或治疗蛋白激酶相关疾病如癌症、自身免疫疾病、神经疾病、代谢性疾病或感染等方面具有有效性。

  公开号：

  KR20190064555A
• 作为产物：
  描述：

  3-氯苯甲酸 、 4-氯-7-氮杂吲哚 以 正庚烷 为溶剂， 以88%的产率得到4-chloro-1H-pyrrolo[2,3-b]pyridine-N-oxide meta-chlorobenzoic acid
  参考文献：
  名称：

  通过 Reissert-Henze 反应首次实用且高效的一锅法合成 6-取代 7-氮杂吲哚

  摘要：

  通过 7-氮杂吲哚-N-氧化物 M-氯苯甲酸盐的选择性 O-甲基化和随后的碱催化一锅反应与一系列 N-、 O-、S-亲核试剂或氰化物。

  DOI：

  10.1055/s-2007-1000853

文献信息

• 신규한 헤테로고리 화합물
  申请人：NeoPharm Co., LTD. (주)네오팜(120000320884) Corp. No ▼ 160111-0100688BRN ▼305-81-38977

  公开号：KR101560536B1

  公开（公告）日：2015-10-16

  본 발명은 신규한 헤테로고리 화합물 또는 이들의 약학적으로 허용되는 염 및 용매화물에 관한 것으로, 이를 유효성분으로 함유하는 약학조성물 또는 화장품 조성물은 피부질환의 치료 또는 예방에 매우 유용하다.

  该发明涉及新型的杂环化合物或其药学上可接受的盐和溶剂化合物，含有其作为有效成分的药学组合物或化妆品组合物对于治疗或预防皮肤疾病非常有用。
• 단백질 키나제 억제제로서의 헤테로고리 화합물
  申请人：HK inno.N Corporation 에이치케이이노엔 주식회사(120140199843) Corp. No ▼ 110111-5379692BRN ▼201-86-38914

  公开号：KR102112336B1

  公开（公告）日：2020-05-18

  본 발명은 단백질 키나제 억제 활성을 갖는 신규 화합물, 이의 입체이성질체 또는 이의 약제학적 허용가능한 염을 제공한다. 본 발명에 따른 화합물, 이의 입체이성질체 또는 이의 약제학적 허용가능한 염은 단백질 키나제 억제 활성을 나타냄으로써, 암, 자가면역질환, 신경질환, 대사질환 또는 감염 등의 단백질 키나제 관련 질환의 예방 또는 치료에 효과적이다.

  本发明提供了具有蛋白激酶抑制活性的新化合物，其立体异构体或药学上可接受的盐。根据本发明的化合物，其立体异构体或药学上可接受的盐通过显示蛋白激酶抑制活性，在预防或治疗蛋白激酶相关疾病，如癌症、自身免疫疾病、神经疾病、代谢性疾病或感染等方面具有有效性。
• [EN] HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE À UTILISER EN TANT QU'INHIBITEUR DE PROTÉINE KINASE
  申请人：CJ HEALTHCARE CORP

  公开号：WO2019078619A1

  公开（公告）日：2019-04-25

  The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.

  本发明提供了一种具有蛋白激酶抑制活性的新化合物，其立体异构体或其药学上可接受的盐。根据本发明的该化合物、其立体异构体或其药学上可接受的盐显示出蛋白激酶抑制活性，因此在预防或治疗与蛋白激酶相关的疾病，如癌症、自身免疫疾病、神经系统疾病、代谢性疾病、感染等方面具有有效性。
• Heterocyclic compound as a protein kinase inhibitor
  申请人：HK inno.N Corporation

  公开号：US11524968B2

  公开（公告）日：2022-12-13

  The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.

  本发明提供了一种具有蛋白激酶抑制活性的新型化合物、其立体异构体或其药学上可接受的盐。 根据本发明的化合物、其立体异构体或其药学上可接受的盐具有蛋白激酶抑制活性，因此可有效预防或治疗与蛋白激酶有关的疾病，如癌症、自身免疫性疾病、神经系统疾病、代谢性疾病、感染或类似疾病。
• 1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT 6 receptor antagonists
  作者：Charles-Henry Fabritius、Ullamari Pesonen、Josef Messinger、Raymond Horvath、Harri Salo、Michał Gałęzowski、Mariusz Galek、Klaudia Stefańska、Joanna Szeremeta-Spisak、Marta Olszak-Płachta、Anna Buda、Justyna Adamczyk、Marcin Król、Peteris Prusis、Magdalena Sieprawska-Lupa、Maciej Mikulski、Katja Kuokkanen、Hugh Chapman、Radosław Obuchowicz、Timo Korjamo、Niina Jalava、Mateusz Nowak

  DOI：10.1016/j.bmcl.2016.04.024

  日期：2016.6

  A series of 1-Sulfonyl-6-Piperazinyl-7-Azaindoles, showing strong antagonistic activity to 5-HT6 receptor (5-HT6R) was synthesized and characterized. The series was optimized to reduce activity on D-2 receptor. Based on the selectivity against this off-target and the analysis of the ADME-tox profile, compound 1c was selected for in vivo efficacy assessment, which demonstrated procognitive effects as shown in reversal of scopolamine induced amnesia in an elevated plus maze test in mice. Compound 3, the demethylated version of compound 1c, was profiled against a panel of 106 receptors, channels and transporters, indicating only D-3 receptor as a major off-target. Compound 3 has been selected for this study over compound 1c because of the higher 5-HT6R/D2R binding ratio. These results have defined a new direction for the design of our pseudo-selective 5-HT6R antagonists. (C) 2016 Elsevier Ltd. All rights reserved.